SEC Form 4 · accession 0001439222-26-000079
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jay T. Backstrom
Director
Period of report
Jun 18, 2026
Accepted (ET)
Jun 23, 2026 · 5:12 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001439222
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted stock unitsF1,F2 | — | Jun 18, 2026 | A | 2,927 | A | — | — | Common stock | 2,927 | 2,927 | D |
| Stock options (right to buy)F3 | $34.16 | Jun 18, 2026 | A | 14,950 | A | — | Jun 18, 2036 | Common stock | 14,950 | 14,950 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F2The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
- F3These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.